Response to hydroxyurea therapy in β‐thalassemia

No abstract is available for this paper.

• Publication year

  2008

• Venue

  American journal of hematology/oncology

• Publication date

  2008-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ajh.21120PMID 18181203
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hydroxyurea use in Lebanese patients with beta-thalassemia intermedia.

  2006cited by this paper
• Hydroxyurea in thalassemia intermedia—a promising therapy

  2005cited by this paper
• Hematologic and Clinical Responses of Thalassemia Intermedia Patients to Hydroxyurea During 6 Years of Therapy in Iran

  2005cited by this paper
• Pharmacological Induction of Fetal Hemoglobin: Why Haven't We Been More Successful in Thalassemia?

  2005cited by this paper
• Fetal haemoglobin augmentation in E/β0 thalassaemia: clinical and haematological outcome

  2005cited by this paper
• Beta-thalassemia.

  2005cited by this paper
• MEDICAL PROGRESS : β-thalassemia

  2005cited by this paper
• Do alpha deletions influence hydroxyurea response in thalassemia intermedia?

  2005cited by this paper
• Paraplegia due to spinal cord compression by extramedullary erythropoietic tissue in a thalassaemia intermedia patient with gynecomastia secondary to cirrhosis: successful treatment with hydroxyurea.

  2004cited by this paper
• Hydroxyurea in the treatment of major β-thalassemia and importance of genetic screening

  2004cited by this paper
• Genetic insights into the clinical diversity of β thalassaemia

  2004cited by this paper
• Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.

  2004cited by this paper
• Flow Cytometric Analysis of Hydroxyurea Effects on Fetal Hemoglobin Production in Cultures of β‐Thalassemia Erythroid Precursors

  2003cited by this paper
• Long‐term hydroxyurea therapy in beta‐thalassaemia patients

  2003cited by this paper
• Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

  2003cited by this paper
• Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia.

  2003cited by this paper
• Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease.

  2003cited by this paper
• Hydroxyurea exerts bi‐modal dose‐dependent effects on erythropoiesis in human cultured erythroid cells via distinct pathways

  2002cited by this paper
• Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis

  2002cited by this paper
• Single-tube multiplex-PCR screen for common deletional determinants of α-thalassemia

  2000cited by this paper
• Single-tube multiplex-PCR screen for common deletional determinants of alpha-thalassemia.

  2000cited by this paper
• Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.

  1999cited by this paper
• Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia

  1999cited by this paper
• Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in β thalassaemia

  1998cited by this paper
• Hydroxyurea Therapy in Thalassemia a

  1998cited by this paper
• Regulation and function of transcription factor GATA-1 during red blood cell differentiation.

  1996cited by this paper
• Hemoglobin switching and fetal hemoglobin reactivation.

  1996cited by this paper
• Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease.

  1996cited by this paper
• Hydroxyurea therapy in beta-thalassaemia intermedia: improvement in haematological parameters due to enhanced beta-globin synthesis.

  1995cited by this paper
• Hydroxyurea therapy in β‐thalassaemia intermedia: improvement in haematological parameters due to enhanced β‐globin synthesis

  1995cited by this paper
• Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

  1995cited by this paper
• Pharmacologic treatment of thalassemia intermedia with hydroxyurea.

  1994cited by this paper
• The amplification refractory mutation system (ARMS): A rapid and direct prenatal diagnostic technique for β‐thalassaemia in Singapore

  1994cited by this paper
• Systematic use of automated fluorescence‐based sequence analysis of amplified genomic DNA for rapid detection of point mutations

  1994cited by this paper
• The amplification refractory mutation system (ARMS): a rapid and direct prenatal diagnostic technique for beta-thalassaemia in Singapore.

  1994cited by this paper
• Treatment with Azacitidine of Patients with End-Stage β-Thalassemia

  1993cited by this paper
• Brief report: treatment with azacitidine of patients with end-stage beta-thalassemia.

  1993cited by this paper
• A case of spinal cord compression by extramedullary haemopoiesis in a thalassaemic patient: a putative role for hydroxyurea?

  1992cited by this paper
• Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea.

  1984cited by this paper

• Efficacy and safety of hydroxyurea therapy on patients with β-thalassemia: a systematic review and meta-analysis

  2025cites this paper
• Treatment Response to Hydroxyurea in Children with Beta Thalassemia

  2025cites this paper
• Beta-Thalassemia: A Pharmacological Drug-Based Treatment

  2024cites this paper
• Pharmacogenomics of Drugs Used in β-Thalassemia and Sickle-Cell Disease: From Basic Research to Clinical Applications

  2024cites this paper
• Thalassaemia—A global view

  2023cites this paper
• Non-Transfusion-Dependent Thalassemia: A Panoramic Review

  2022cites this paper
• A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia

  2022cites this paper
• IVS I-5 (G > C) is associated with changes to the RBC membrane lipidome in response to hydroxyurea treatment in β-thalassemia patients.

  2022cites this paper
• Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development

  2021cites this paper
• A Pragmatic Scoring Tool to Predict Hydroxyurea Response Among β-Thalassemia Major Patients in Pakistan

  2021cites this paper
• Revisiting fetal hemoglobin inducers in beta-hemoglobinopathies: a review of natural products, conventional and combinatorial therapies

  2021cites this paper
• Genome-based therapeutic interventions for β-type hemoglobinopathies

  2021cites this paper
• Effect of the Hydoxyurea in Yemeni Transfusion-Dependent β-Thalassemia Patients

  2020cites this paper
• Screening Readthrough Compounds to Suppress Nonsense Mutations: Possible Application to β-Thalassemia

  2020cites this paper
• β-Hemoglobinopathies: The Test Bench for Genome Editing-Based Therapeutic Strategies

  2020cites this paper
• Association of Exon 14 of the SOX6 Gene Sequence Variations with Response to Hydroxyurea Therapy in Patients Carrying Non Transfusion-Dependent Thalassemia

  2020cites this paper
• Longitudinal Description of Gonadal Function in Sickle-cell Patients Treated With Hematopoietic Stem Cell Transplant Using Alkylator-based Conditioning Regimens

  2020cites this paper
• Genomic variants in members of the Krüppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in β-hemoglobinopathies patients.

  2019cites this paper
• Hydroxyurea (hydroxycarbamide) for transfusion-dependent β-thalassaemia.

  2019cites this paper
• The Effect of Xmn1 Gene Polymorphism on Blood Transfusion Dependency and Hemoglobin Concentration among Iranian Thalassemia Patients with IVSII-1 Mutation

  2019cites this paper
• β-Thalassemia intermedia: a comprehensive overview and novel approaches

  2018cites this paper
• Hydroxyurea responses in clinically varied beta, HbE-beta thalassaemia and sickle cell anaemia patients of Eastern India

  2018cites this paper
• Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia

  2018cites this paper
• Metallomic profiling to evaluate the response to drug treatment: hydroxyurea as a case study in β-thalassemia patients

  2017cites this paper
• Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients

  2017cites this paper
• Hydroxyurea for lifelong transfusion-dependent β-thalassemia: A meta-analysis

  2017cites this paper
• Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/β-thalassemia patients.

  2016cites this paper
• Hydroxyurea for ß-thalassaemia major

  2016cites this paper
• Prevalence of Pulmonary Hypertension in Patients with Thalassemia Intermedia in 2009: a single center’s experience

  2015cites this paper
• Treatment Response to Hydroxyurea in Beta Thalassemia

  2015cites this paper
• Pharmacogenomics for Haemoglobinopathies Therapeutics

  2015cites this paper
• Comparative Study of Radiographic and Laboratory Findings Between Beta Thalassemia Major and Beta Thalassemia Intermedia Patients With and Without Treatment by Hydroxyurea

  2015cites this paper
• The effects of hydroxyurea and bone marrow transplant on Anti-Müllerian hormone (AMH) levels in females with sickle cell anemia.

  2015cites this paper
• XmnI polymorphism: Relation to β-thalassemia phenotype and genotype in Egyptian Children

  2015cites this paper
• Efeito da hidroxiureia na adesão in vitro de neutrófilos, sob condições inflamatórias = : Effect of hydroxyurea on the adhesion of neutrophil under in vitro inflammatory conditions

  2015cites this paper
• Meta-analysis on effectiveness of hydroxyurea to treat transfusion-dependent beta-thalassemia

  2015cites this paper
• The Effect and Side Effect of Hydroxyurea Therapy on Patients With β-Thalassemia: A Systematic Review to December 2012

  2014influential citation
• Report on Patients with Non Transfusion-Dependent β-Thalassemia Major Being Treated with Hydroxyurea Attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013

  2014cites this paper
• Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years’ follow-up in Egypt

  2014cites this paper
• Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients.

  2014cites this paper
• Hydroxyurea Treatment in Transfusion-Dependent β-Thalassemia Patients

  2014cites this paper
• Frequency of Cholelithiasis in Patients With Beta-Thalassemia Intermedia With and Without Hydroxyurea

  2014cites this paper
• G&ggr;-Xmn I Polymorphism: A Significant Determinant of &bgr;-Thalassemia Treatment Without Blood Transfusion

  2013cites this paper
• Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.

  2013cites this paper
• Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?

  2013cites this paper
• Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity

  2013cites this paper
• Frequency of GG-globin promoter -158 (CT) Xmn I polymorphism in Denizli, Turkey

  2012influential citation
• The XmnI and BCL11A Single Nucleotide Polymorphisms May Help Predict Hydroxyurea Response in Iranian β-Thalassemia Patients

  2012cites this paper
• Pluripotent stem cells in research and treatment of hemoglobinopathies.

  2012cites this paper
• The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia.

  2012cites this paper
• Combination of two rare mutations causes β-thalassaemia in a Bangladeshi patient

  2011cites this paper
• Genotype–phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran

  2011influential citation
• Clinicopathological and Radiological Study of Egyptian β-Thalassemia Intermedia and β-Thalassemia Major Patients: Relation to Complications and Response to Therapy

  2011cites this paper
• Labdane diterpenes from the aerial parts of Curcuma comosa enhance fetal hemoglobin production in an erythroid cell line.

  2010cites this paper
• Hematopoietic stem cell transplantation for hemoglobinopathies: current practice and emerging trends.

  2010cites this paper
• Non‐transferrin bound labile plasma iron and iron overload in Sickle Cell Disease: a comparative study between Sickle Cell Disease and β thalassemic patients

  2010cites this paper
• Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.

  2009cites this paper
• Possible graft‐versus‐host disease involving the central nervous system soon after cord blood transplantation

  2009cites this paper
• Fetal Globin Induction in β-thalassemia

  2009cites this paper
• Hydroxyurea in the Management of Thalassemia Intermedia

  2009cites this paper
• Uncertainty and discordance in the staging and prognosis of diffuse large B‐cell lymphoma with isolated bilateral testicular involvement

  2009cites this paper
• Pediatric Radiology : Cord Compression due to Extramedullary Hematopoiesis in an Adolescent with Known Beta Thalassemia Major Soman

  2009cites this paper
• Monocytes from patients with myelodysplastic syndromes are more resistant to inhibition by thalidomide

  2009cites this paper
• Hydroxycarbamide‐induced dermopathy

  2009cites this paper
• Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies

  2009cites this paper
• HYDROXYUREA-INDUCED HEMATOLOGICAL RESPONSE IN TRANSFUSION-INDEPENDENT BETA-THALASSEMIA INTERMEDIA: Case Series and Review of Literature

  2009cites this paper
• Treatment with hydroxyurea in a patient compound heterozygote for a high oxygen affinity hemoglobin and β‐thalassemia minor

  2009cites this paper
• Production of β‐globin and adult hemoglobin following G418 treatment of erythroid precursor cells from homozygous β039 thalassemia patients

  2009cites this paper
• Thalassemia and its relevance to personalized medicine.

  2008cites this paper
• Molecular Basis Of Thalassemia Intermedia In Pakistani Population

  2008cites this paper